2014
Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)
Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). Journal Of Clinical Oncology 2014, 32: 2311-2317. PMID: 24934787, PMCID: PMC4105484, DOI: 10.1200/jco.2013.53.7142.Peer-Reviewed Original ResearchConceptsRelapse-free survivalSingle-agent paclitaxelOverall survivalHazard ratioBreast cancerTreatment-related deathsCycles of therapyOperable breast cancerPositive axillary nodesPrimary end pointDuration of therapyOptimal adjuvant chemotherapyComparison of doxorubicinAdjuvant chemotherapyCALGB 40101Median followAdjuvant therapyHematologic toxicityPositive nodesAxillary nodesPatient deathBalance efficacyPatientsEnd pointTherapy
2013
Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.
Shulman L, Berry D, Cirrincione C, Becker H, Perez E, O'Regan R, Martino S, Shapiro C, Atkins J, Schneider C, Kimmick G, Burstein H, Norton L, Muss H, Hudis C, Winer E. Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101. Journal Of Clinical Oncology 2013, 31: 1007-1007. DOI: 10.1200/jco.2013.31.15_suppl.1007.Peer-Reviewed Original ResearchRelapse-free survivalHazard ratioOverall survivalBreast cancerEarly-stage breast cancerCycles of therapyNon-hematologic toxicitiesOperable breast cancerPositive axillary nodesSingle-agent paclitaxelTreatment-related deathsOptimal adjuvant chemotherapyStage breast cancerConfidence intervalsComparison of doxorubicinAdjuvant chemotherapyCALGB 40101Hematologic toxicityAdjuvant therapyPositive nodesPrimary endpointAxillary nodesVs. 4Conclusion of equivalenceGrade 3
2009
Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age.
Lichtman S, Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H. Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age. Cancer Research 2009, 69: 6112. DOI: 10.1158/0008-5472.sabcs-6112.Peer-Reviewed Original ResearchFirst-line therapyLines of therapyBreast cancerPatient ageOlder womenSide effectsLine therapyOlder adultsIncidence of gradeOnset of gradePrior chemotherapy regimenSecond-line patientsSingle-agent paclitaxelDoses of paclitaxelMetastatic breast cancerOnset of neurotoxicityRisk of fallsStandard prognostic variablesAge categoriesLikelihood of responseBetter performance scoresPerformance scoresBilirubin elevationPaclitaxel efficacyWeekly paclitaxel
2006
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806
Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H, for the Cancer and Leukemia Group B. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Research And Treatment 2006, 100: 301-308. PMID: 16773437, DOI: 10.1007/s10549-006-9251-7.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerInterleukin-6Breast cancerP-glycoproteinPgp expressionMultidrug resistance protein-1 expressionSingle-agent paclitaxelElevated serum levelsBreast cancer patientsBreast cancer cell linesProtein-1 expressionResult of cancerMulti-drug resistanceCancer cell linesClinical characteristicsOverall survivalPartial responseSerum levelsTreatment armsWorse prognosisPredictive factorsCancer patientsPredictive markerIHC expressionPaclitaxel sensitivity